Immunitybio announces insurance coverage of anktiva® across multiple states with first commercial doses administered just weeks after fda approval—opening new era for immunotherapy beyond checkpoint inhibitors

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx) today announced the initial treatment of multiple patients in the united states to receive therapy with anktiva® (nogapendekin alfa inbakicept-pmln), immunitybio's recently approved immunotherapy for bacillus calmette-guÉrin (bcg)-unresponsive non-muscle invasive bladder cancer (nmibc) carcinoma in situ. anktiva was approved by the u.s. food and drug administration (fda) on april 22, 2024 for the treatment of patients with b.
IBRX Ratings Summary
IBRX Quant Ranking